Matthew Pauls Biography and Net Worth

Mr. Pauls has served as Savara’s Chief Executive Officer since December 2020, Chair of the Board of Directors since September 2020, and the Company’s Interim Chief Executive Officer from September 2020 to December 2020. He has been a member of Savara’s Board of Directors since April 2017 and was a member of Mast Therapeutics’ Board of Directors from October 2015 to April 2017. Previously, Mr. Pauls was the founder of Spartan Biopharma Insights, LLC, where he provided strategic advisement to institutional investors, C-suite executives, board directors, et al on investment thesis assessment, capitalization strategy, mergers and acquisitions, clinical execution, and commercialization. He also previously served on the Board of Directors of Zyla Life Sciences, which merged with Assertio Therapeutics in 2020. From August 2014 to November 2019, Mr. Pauls was President, Chief Executive Officer and (from October 2015 – November 2019) a member of the Board of Directors of Strongbridge Biopharma plc, a publicly traded biopharmaceutical company that he took public onto NASDAQ via IPO in October 2015. Strongbridge is focused on therapies that target rare diseases. From April 2013 to August 2014, Mr. Pauls was Chief Commercial Officer of Insmed, Inc., a publicly traded global biopharmaceutical company focused on rare diseases. Prior to Insmed, he worked at Shire Pharmaceuticals, a global specialty biopharmaceutical company, from 2007 to 2013, most recently as Senior Vice President, Head of Global Commercial Operations. Earlier in his career, Mr. Pauls held senior commercial leadership positions at Bristol-Myers Squibb and Johnson & Johnson in various U.S. and global commercial roles. Mr. Pauls holds B.S. and M.B.A. degrees from Central Michigan University and a J.D. from Michigan State University College of Law.